VTVT Share Price | vTv Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does vTv Therapeutics, Inc. do?

Overview:vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) Market cap: USD 50.23 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -3.91 Return on Equity: -291.62% Price to Book: 6.34Contact Details:Address: 3980 Premier Dr, Suite 310, HIGH POINT NC: 27265 Tel: 1 336 8410300 Fax: 1 336 8410310 Website: http://vtvtherapeutics.com/

Q: Is vTv Therapeutics, Inc. overvalued or undervalued?

As of 15 May 2025, the valuation grade for vTv Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company appears to be overvalued given its current metrics, with a price-to-book value of 6.58 and negative ratios for EV to EBIT and EV to EBITDA at -0.85. Additionally, the return on equity (ROE) is alarmingly low at -291.62%, reflecting severe inefficiencies in generating profit from equity.In comparison to its peers, vTv Therapeutics shows a stark contrast, with Rezolute, Inc. and SELLAS Life Sciences Group, Inc. also classified as not qualifying, but with less extreme valuations of -4.90 and -5.73 for their respective EV to EBITDA ratios. The industry as a whole is struggling, but vTv's metrics suggest it is particularly vulnerable. Furthermore, the stock has underperformed significantly against the S&P 500 over various time frames, including a 1-year return of -19.38% compared to the index's 10.26%. Overall, vTv Therapeutics is assessed as overvalued in the current market environment.

Q: Is vTv Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for vTv Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, supporting the positive outlook. Bollinger Bands are bullish on both weekly and monthly time frames. The KST is mildly bullish on both weekly and monthly as well, indicating some upward momentum. However, the daily moving averages are mildly bearish, which presents a mixed signal. The stock has outperformed the S&P 500 significantly over the past week (6.42% vs. 1.05%) and month (37.56% vs. 2.33%), but it has underperformed over longer periods, particularly the 3-year and 5-year returns. Overall, the current technical stance is mildly bullish, driven primarily by the MACD and Bollinger Bands.

Results Declared: vTv Therapeutics, Inc. has declared results on 10 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

30.6 k

Shareholding (Dec 2025)

FII

0.04%

Held by 4 FIIs

DII

78.85%

Held by 10 DIIs

Promoter

11.72%

How big is vTv Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, vTv Therapeutics, Inc. has a market capitalization of 50.23 million and reported net sales of 0.02 million with a net profit of -22.91 million over the last four quarters. Shareholder's funds are 12.20 million, and total assets amount to 38.27 million.

View full answer

What does vTv Therapeutics, Inc. do?

22-Jun-2025

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered small molecule drug candidates. It has a market cap of $50.23 million and reported a net profit loss of $6 million as of March 2025.

View full answer

Who are in the management team of vTv Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of vTv Therapeutics, Inc. includes Executive Chairman Ms. Robin Abrams and Board members Mr. Hersh Kozlov, Mr. Richard Nelson, Mr. John Fry, Mr. Noel Spiegel, and Dr. Howard Weiner.

View full answer

Is vTv Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 15, 2025, vTv Therapeutics, Inc. is assessed as overvalued with a valuation grade of "does not qualify" due to poor financial metrics, including a price-to-book ratio of 6.58, negative EV to EBIT and EV to EBITDA ratios, and a return on equity of -291.62%, significantly underperforming against the S&P 500.

View full answer

Is vTv Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, vTv Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and Bollinger Bands, despite mixed signals from daily moving averages and underperformance over longer periods.

View full answer

Compare vTv Therapeutics, Inc. with Similar Stocks

Bolt Biotherapeutics, Inc.Daré Bioscience, Inc.Fortress Biotech, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 159 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.39

Return on Equity

-40.29%

Price to Book

2.26

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

3.69%

6 Months

68.63%

1 Year

71.51%

2 Years

78.93%

3 Years

4537.38%

4 Years

34.01%

5 Years

-67.97%

vTv Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-12.46%

EBIT to Interest (avg)

-21.61

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-3.91

Sales to Capital Employed (avg)

0.03

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

33.20%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.26

EV to EBIT

-2.05

EV to EBITDA

-2.06

EV to Capital Employed

-2.22

EV to Sales

61.20

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-40.29%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (9.39%)

Foreign Institutions

Held by 4 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 31.07% vs -39.19% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.90",
          "val2": "-10.70",
          "chgp": "26.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.10",
          "val2": "-10.30",
          "chgp": "31.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -100.00% vs 0.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -37.00% vs 12.69% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-32.80",
          "val2": "-24.10",
          "chgp": "-36.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.10",
          "val2": "-22.70",
          "chgp": "-37.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-23,775.80%",
          "chgp": "2,377.58%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.90

-10.70

26.17%

Interest

0.00

Exceptional Items

-0.00

Consolidate Net Profit

-7.10

-10.30

31.07%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 31.07% vs -39.19% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

1.00

-100.00%

Operating Profit (PBDIT) excl Other Income

-32.80

-24.10

-36.10%

Interest

0.00

Exceptional Items

-0.00

-0.10

100.00%

Consolidate Net Profit

-31.10

-22.70

-37.00%

Operating Profit Margin (Excl OI)

0.00%

-23,775.80%

2,377.58%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -100.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -37.00% vs 12.69% in Dec 2024

All Annual Results

Company CV

About vTv Therapeutics, Inc.

vTv Therapeutics, Inc.

Pharmaceuticals & Biotechnology

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Company Coordinates

Company Details

3980 Premier Dr, Suite 310 , HIGH POINT NC : 27265

Tel: 1 336 8410300

http://vtvtherapeutics.com/

Registrar Details